REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

Cachexia

From Molecular Insights to Clinical Strategies: Delve into the complexities of cachexia, encompassing cancer cachexia, molecular mechanisms, and evolving therapeutic approaches. Discover the forefront of research aimed at understanding and combating this debilitating condition.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopenia

-mutated NSCLC is Dependent on Tumor-secreted GDF15.

Cachexia is a wasting syndrome comprised of adipose, muscle, and weight loss observed in cancer patients. Tumor loss-of-function mutations in , a regulator of the energy sensor AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are associated...
🗓️ 2024-06-17
Read More-mutated NSCLC is Dependent on Tumor-secreted GDF15.

Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

For many patients, the cancer continuum includes a syndrome known as cancer-associated cachexia (CAC), which encompasses the unintended loss of body weight and muscle mass, and is often associated with fat loss, decreased appetite, lower tolerance and poorer response to...
🗓️ 2024-06-27
Read MoreDefining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

Assessing cachexia in obesity: contradiction or perfectly possible?

Existing definitions of clinically important weight loss in patients with cancer do not specifically address weight loss in patients who are obese at presentation. This review explores the clinical impact of weight loss and depletion of the skeletal muscle mass...
🗓️ 2024-07-04
📰 Publication: Current Opinion In Clinical Nutrition And Metabolic Care
Read MoreAssessing cachexia in obesity: contradiction or perfectly possible?

Validity of dietary intake methods in cancer cachexia.

Accurate assessment of dietary intake, especially energy and protein intake, is crucial for optimizing nutritional care and outcomes in patients with cancer. Validation of dietary assessment methods is necessary to ensure accuracy, but the validity of these methods in patients...
🗓️ 2024-07-08
📰 Publication: Current Opinion In Supportive And Palliative Care
Read MoreValidity of dietary intake methods in cancer cachexia.

Skeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Cancer cachexia is an involuntary loss of body weight, mostly of skeletal muscle. Previous research favors the existence of a microbiota-muscle crosstalk, so the aim of the study was to evaluate the impact of microbiota alterations induced by antibiotics on...
🗓️ 2024-06-19
📰 Publication: Journal Of Proteome Research
Read MoreSkeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Circulating adipose-tissue miRNAs in gastrointestinal cancer patients and their association with the level and type of adiposity at body composition analysis.

Adipose tissue (AT) wasting in cancer is an early catabolic event with negative impact on outcomes. Circulating miRNAs may promote body weight loss and cachexia. We measured circulating miRNAs linked to AT alterations and compared their levels between i) gastrointestinal...
🗓️ 2024-07-30
Read MoreCirculating adipose-tissue miRNAs in gastrointestinal cancer patients and their association with the level and type of adiposity at body composition analysis.

Survey on the knowledge and practices in anorexia of aging diagnosis and management in Japan.

Anorexia of aging (AA) is a condition in older adults that includes loss of appetite and reduced food intake. There is a lack of detailed analysis of the potential influence of educational initiatives in addressing AA. This study aimed to...
🗓️ 2024-08-21
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSurvey on the knowledge and practices in anorexia of aging diagnosis and management in Japan.

Targeted nutritional intervention attenuates experimental lung cancer cachexia.

Cachexia, a syndrome with high prevalence in non-small cell lung cancer patients, impairs quality of life and reduces tolerance and responsiveness to cancer therapy resulting in decreased survival. Optimal nutritional care is pivotal in the treatment of cachexia and a...
🗓️ 2024-07-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeted nutritional intervention attenuates experimental lung cancer cachexia.

KLF10: a point of convergence in cancer cachexia.

Cancer-associated cachexia is a wasting syndrome entailing loss in body mass and a shortened life expectancy. There is currently no effective treatment to abrogate this syndrome, which leads to 20-30% of deaths in patients with cancer. While there have been...
🗓️ 2024-07-15
📰 Publication: Current Opinion In Supportive And Palliative Care
Read MoreKLF10: a point of convergence in cancer cachexia.

Preventing loss of sirt1 lowers mitochondrial oxidative stress and preserves C2C12 myotube diameter in an in vitro model of cancer cachexia.

Cancer cachexia is a multifactorial syndrome associated with advanced cancer that contributes to mortality. Cachexia is characterized by loss of body weight and muscle atrophy. Increased skeletal muscle mitochondrial reactive oxygen species (ROS) is a contributing factor to loss of...
🗓️ 2024-07-01
Read MorePreventing loss of sirt1 lowers mitochondrial oxidative stress and preserves C2C12 myotube diameter in an in vitro model of cancer cachexia.

The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages...
🗓️ 2024-03-29
📰 Publication: Cancer Cell
Read MoreThe crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Finding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1-year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (P MRS) in a...
🗓️ 2024-04-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial infections, and renal damage. Nutritional disorders, especially malnutrition, are noted in about 35-71% of MM patients....
🗓️ 2024-03-24
Read MorePolymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on...
🗓️ 2023-12-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEfficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

CACHEXIA DEFINITION

Cachexia has been defined as a loss of lean tissue mass, involving a weight loss greater than 5% of body weight in 12 months or less in the presence of chronic illness or as a body mass index (BMI) lower than 20 kg/m2. In addition, usually three of the following five criteria are required: decreased muscle strength, fatigue, anorexia, low fat-free mass index, increase of inflammation markers such as C-reactive protein or interleukin (IL)-6 as well as anaemia or low serum albumin.

Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.

REFERENCES
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!